Matrix begins two U.S. cancer trials

MATX began a 15-patient, dose-escalating Phase I trial of its FMdC anticancer agent combined with 5-fluorouracil (5-FU), and began a 15-patient Phase I/II trial of FMdC combined with cisplatin. FMdC, ...